Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study

In this study, we aimed to complement previous phenotypic studies by doing an international study of age at symptom onset, age at death, and disease duration in individuals with mutations in GRN, MAPT, and C9orf72.MethodsIn this international, retrospective cohort study, we collected data on age at symptom onset, age at death, and disease duration for patients with pathogenic mutations in the GRN and MAPT genes and pathological expansions in the C9orf72 gene through the Frontotemporal Dementia Prevention Initiative and from published papers. We used mixed effects models to explore differences in age at onset, age at death, and disease duration between genetic groups and individual mutations. We also assessed correlations between the age at onset and at death of each individual and the age at onset and at death of their parents and the mean age at onset and at death of their family members. Lastly, we used mixed effects models to investigate the extent to which variability in age at onset and at death could be accounted for by family membership and the specific mutation carried.FindingsData were available from 3403 individuals from 1492 families: 1433 with C9orf72 expansions (755 families), 1179 with GRN mutations (483 families, 130 different mutations), and 791 with MAPT mutations (254 families, 67 different mutations). Mean age at symptom onset and at death was 49·5 years (SD 10·0; onset) and 58·5 years (11·3; death) in the MAPT group, 58·2...
Source: The Lancet Neurology - Category: Neurology Source Type: research

Related Links:

CONCLUSIONS: ¹⁸F-FC119S PET provides high sensitivity and specificity in detecting AD and therefore may be considered a useful diagnostic tool for AD. PMID: 31942769 [PubMed]
Source: Journal of Clinical Neurology - Category: Neurology Tags: J Clin Neurol Source Type: research
Purpose of review The incidence of Alzheimer's disease is increasing. Premortem diagnosis of Alzheimer's disease is now possible but require invasive and expensive testing such as PET amyloid beta binding and/or spinal fluid amyloid beta levels. There is a great need for minimally invasive and inexpensive biomarkers to allow for early diagnosis and intervention. Recent findings There has been a large volume of literature assessing ocular biomarkers for Alzheimer's disease. Much of the research to date has significant limitations, including sample size, variable diagnostic criteria for Alzheimer's disease, lack of biom...
Source: Current Opinion in Neurology - Category: Neurology Tags: NEURO-OPHTHALMOLOGY: Edited by Heather E. Moss Source Type: research
This report calls on government to invest in six priority research areas, which will help to deliver a life-changing treatment for dementia by doubling research funding and speeding up trials for new treatments.ReportAlzheimer's Research UK - press release
Source: Health Management Specialist Library - Category: UK Health Authors: Tags: Mental Health Source Type: blogs
CONCLUSIONS: The type and characteristics of CS exercises have an impact on the engagement level of AD patients with mild to moderate dementia. Further studies are necessary to better understand which characteristics of the exercises affect the engagement of the patient according to their particularities. This kind of study may help the design of CS sessions and improve the results obtained. PMID: 31940610 [PubMed - as supplied by publisher]
Source: Dementia and Geriatric Cognitive Disorders - Category: Psychiatry Tags: Dement Geriatr Cogn Disord Source Type: research
Authors: Sittler MC, Meichsner F, Wilz G Abstract The present study examined the factor structure of a German questionnaire version of the Behavioral Pathology in Alzheimer's Disease Scale (BEHAVE-AD), which originally assesses behavioral disturbances in people with dementia independent from cognitive symptoms in a clinical interview with a caregiver. The 7-factor structure of the interview version of the BEHAVE-AD (i. e., Paranoid and Delusional Ideation, Hallucinations, Activity Disturbances, Aggressiveness, Diurnal Rhythm Disturbances, Affective Disturbances, Anxieties and Phobias) could not be confirmed ...
Source: PPmP Psychotherapie Psychosomatik Medizinische Psychologie - Category: Psychiatry & Psychology Tags: Psychother Psychosom Med Psychol Source Type: research
Publication date: Available online 14 January 2020Source: NeuroImage: ClinicalAuthor(s): Kathryn M. Broadhouse, Maria Fiatarone Singh, Chao Suo, Nicola Gates, Wei Wen, Henry Brodaty, Nidhi Jain, Guy C. Wilson, Jacinda Meiklejohn, Nalin Singh, Bernhard T. Baune, Michael Baker, Nasim Foroughi, Yi Wang, Nicole Kochan, Kevin Ashton, Matt Brown, Zhixiu Li, Yorgi Mavros, Perminder S. SachdevABSTRACTDementia affects 47 million individuals worldwide, and assuming the status quo is projected to rise to 150 million by 2050. Prevention of age-related cognitive impairment in older persons with lifestyle interventions continues to garn...
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
(Alzheimer's Association) Phase 3 drug trial results on improving sleep for persons living with Alzheimer's disease. The US Hispanic/Latino population is predicted to have the largest increase in Alzheimer's and all dementia by mid-century. Artificial intelligence may help with early detection of dementia.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Source: Neuropsychiatric Disease and Treatment - Category: Psychiatry Tags: Neuropsychiatric Disease and Treatment Source Type: research
Authors: Orso B, Mattei C, Arnaldi D, Massa F, Serafini G, Plantone D, Doglione E, Grafman J, Nobili F, Pardini M Abstract OBJECTIVE: As an analogy with mild cognitive impairment (MCI), the mild behavioral impairment (MBI) construct has been proposed as a diagnostic label for those presenting late-onset behavioral symptoms. To date, however, the clinical, cognitive, and structural imaging features associated with an increased risk of conversion from MBI to dementia are poorly understood. METHODS: We retrospectively analyzed the cognitive performance and structural brain MRI of 113 subjects, with a clinical foll...
Source: The American Journal of Geriatric Psychiatry - Category: Psychiatry Tags: Am J Geriatr Psychiatry Source Type: research
(Regenstrief Institute) In the first randomized controlled trial to evaluate pros and cons of population screening for dementia, Regenstrief Institute and Indiana University School of Medicine researchers found no harm, as measured by patient reported depressive and anxiety symptoms, from screening for Alzheimer's disease and related dementia in diverse rural, suburban and urban primary care clinics.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Alzheimer's | Brain | Dementia | Environmental Health | Genetics | National Institute for Health Research (NIHR) | Neurology | Research | Study